EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Ann S Forrest iD, Priyanka Majety, Stéphanie B Mayer, Om P Ganda iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 10961-10976

DOI: 10.1111/dom.71180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 24.08.2026. Verfasst von Ann S Forrest und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, Virginia Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Dyslipidemias, Cardiovascular Diseases, Renal Insufficiency, Chronic, Diabetic Nephropathies. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an atherogenic lipid profile that accelerates atherosclerosis and vascular dysfunction. While statins remain the cornerstone of lipid‐lowering therapy, their cardiovascular benefits decline in advanced CKD. Combination therapy with ezetimibe and newer agents, including PCSK9 inhibitors and bempedoic acid, has shown further cardiovascular risk reduction in CKD. Emerging therapies targeting alternative pathways may address residual lipid abnormalities not corrected by traditional treatments but require longer‐term outcome data in people with DM and CKD. As the prevalence of both conditions rises, applying multifaceted lipid‐lowering strategies may yield the greatest reduction in cardiovascular events and improve survival among this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasCardiovascular DiseasesRenal Insufficiency, ChronicDiabetic NephropathiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsEzetimibe

Stichwörter der Autor:innen

cardiovascular riskchronic kidney diseasediabetes mellitusdyslipidaemiaemerging therapieslipid‐lowering therapy

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsEzetimibe

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes and Metabolism, Virginia Commonwealth University, Richmond, Virginia, USA.
  • Division of Endocrinology, Diabetes and Metabolism, Richmond VAMC, Richmond, Virginia, USA.
  • Department of Endocrinology, Joslin Diabetes Center, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Ann S Forrest, Om P Ganda

Zitieren

APA

Forrest, A. S., Majety, P., Mayer, S. B., & Ganda, O. P. (2026). Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health. Diabetes, Obesity and Metabolism, 28(12), 10961-10976. https://doi.org/10.1111/dom.71180

Vancouver

Forrest AS, Majety P, Mayer SB, Ganda OP. Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health. Diabetes, Obesity and Metabolism. 2026;28(12):10961-10976. doi:10.1111/dom.71180

BibTeX
@article{Forrest2026,
  author = {Forrest, Ann S and Majety, Priyanka and Mayer, Stéphanie B and Ganda, Om P},
  title = {Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {10961--10976},
  doi = {10.1111/dom.71180}
}
Kostenlos starten →